Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorolla, Anabel, Wang, Edina, Golden, Emily, Duffy, Ciara, Henriques, Sónia T., Redfern, Andrew D., Blancafort, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002299/
https://www.ncbi.nlm.nih.gov/pubmed/31636382
http://dx.doi.org/10.1038/s41388-019-1056-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002299/
https://www.ncbi.nlm.nih.gov/pubmed/31636382
http://dx.doi.org/10.1038/s41388-019-1056-3

Ejemplares similares